Goldman Sachs Group Inc Fate Therapeutics Inc Transaction History

Goldman Sachs Group Inc

$706 Billion
Q2 2025

A detailed history of Goldman Sachs Group Inc transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Goldman Sachs Group Inc holds 2,511,676 shares of FATE stock, worth $2.41 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,511,676

Previous 2,458,974 2.14%

Holding current value

$2.41 Million

Previous $1.94 Million 44.85%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$0.68 - $1.67 $35,837 - $88,012	52,702 Added 2.14%	2,511,676 $2.81 Million
Q1 2025 May 09, 2025	SELL	$0.79 - $1.87 $13,777 - $32,612	-17,440 Reduced 0.7%	2,458,974 $1.94 Million
Q4 2024 Feb 11, 2025	SELL	$1.61 - $3.35 $558,652 - $1.16 Million	-346,989 Reduced 12.29%	2,476,414 $4.09 Million
Q3 2024 Nov 14, 2024	BUY	$3.12 - $5.57 $1.48 Million - $2.64 Million	474,849 Added 20.22%	2,823,403 $9.88 Million
Q2 2024 Aug 13, 2024	BUY	$3.26 - $7.08 $1.1 Million - $2.38 Million	336,296 Added 16.71%	2,348,554 $7.7 Million
Q1 2024 May 15, 2024	BUY	$3.54 - $8.35 $5.03 Million - $11.9 Million	1,421,265 Added 240.49%	2,012,258 $14.8 Million
Q4 2023 Feb 13, 2024	BUY	$1.65 - $3.94 $159,269 - $380,316	96,527 Added 19.52%	590,993 $2.21 Million
Q3 2023 May 14, 2024	SELL	$2.02 - $5.04 $194,984 - $486,496	-96,527 Reduced 16.33%	494,466 $1.05 Million
Q3 2023 Nov 14, 2023	SELL	$2.02 - $5.04 $1.19 Million - $2.98 Million	-590,367 Reduced 54.42%	494,466 $1.05 Million
Q2 2023 May 14, 2024	SELL	$4.76 - $6.59 $1.16 Million - $1.61 Million	-243,828 Reduced 18.35%	1,084,833 $5.16 Million
Q2 2023 Aug 14, 2023	SELL	$4.76 - $6.59 $1.16 Million - $1.61 Million	-243,828 Reduced 18.35%	1,084,833 $5.16 Million
Q1 2023 May 14, 2024	BUY	$4.24 - $11.12 $2.2 Million - $5.77 Million	518,625 Added 64.02%	1,328,661 $7.57 Million
Q1 2023 May 11, 2023	BUY	$4.24 - $11.12 $2.2 Million - $5.77 Million	518,625 Added 64.02%	1,328,661 $7.57 Million
Q4 2022 May 14, 2024	SELL	$9.86 - $23.83 $2.28 Million - $5.52 Million	-231,691 Reduced 22.24%	810,036 $8.17 Million
Q4 2022 Feb 13, 2023	SELL	$9.86 - $23.83 $2.28 Million - $5.52 Million	-231,691 Reduced 22.24%	810,036 $8.17 Million
Q3 2022 May 14, 2024	SELL	$21.04 - $36.06 $903,520 - $1.55 Million	-42,943 Reduced 3.96%	1,041,727 $23.3 Million
Q3 2022 Nov 10, 2022	SELL	$21.04 - $36.06 $903,520 - $1.55 Million	-42,943 Reduced 3.96%	1,041,727 $23.3 Million
Q2 2022 May 14, 2024	BUY	$17.78 - $42.39 $8.78 Million - $20.9 Million	493,677 Added 83.53%	1,084,670 $26.9 Million
Q2 2022 Aug 15, 2022	BUY	$17.78 - $42.39 $15.3 Million - $36.4 Million	858,193 Added 378.93%	1,084,670 $26.9 Million
Q1 2022 May 16, 2022	SELL	$29.67 - $60.28 $5.36 Million - $10.9 Million	-180,694 Reduced 44.38%	226,477 $8.78 Million
Q4 2021 Feb 14, 2022	SELL	$47.84 - $64.34 $7.83 Million - $10.5 Million	-163,752 Reduced 28.68%	407,171 $23.8 Million
Q3 2021 Nov 10, 2021	BUY	$59.27 - $95.73 $33.8 Million - $54.7 Million	570,923 New	570,923 $33.8 Million

Others Institutions Holding FATE

# of Institutions

150

Shares Held

83.4M

Call Options Held

179K

Put Options Held

13.4K

View Full List

About FATE THERAPEUTICS INC

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $93.1M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

More about FATE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account

Goldman Sachs Group Inc Fate Therapeutics Inc Transaction History